Treatment with the TGF-β receptor inhibitor, anti-GITR, or GITRL-Fc alone did not prolong the survival of glioma-bearing mice, whereas the combined modulation of the two immune checkpoints led to a higher fraction of long-term surviving mice (Fig. 5D, Suppl. The gene discussed is TNFSF18; the disease is central nervous system cancer.